Point72 Hong Kong’s Humacyte HUMA Stock Holding History

Point72 Hong Kong’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,395	Closed	-$4K	–	2138
2022 Q2	$4K	Buy	+1,395	New	+$7.76K	﹤0.01%	1746

Other funds holding HUMA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

YCMGA

York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Point72 Hong Kong's HUMA Position: Q3 2022 in Review

Point72 Hong Kong sold out of Humacyte (HUMA) in Q3 2022, closing a stake of 1,395 shares — an estimated $4K sold.

Point72 Hong Kong first reported a position in HUMA in Q2 2022 and held it in 1 quarter. The position peaked at $4K in Q2 2022. 70 funds tracked by Wall St. Rank hold HUMA as of Q3 2022.

Point72 Hong Kong reported no remaining Humacyte position as of Q3 2022 after selling out during the quarter.
Point72 Hong Kong sold 1,395 Humacyte shares in Q3 2022, an estimated $4K.
Point72 Hong Kong first reported a position in Humacyte in Q2 2022 and held it in 1 quarter.
Point72 Hong Kong's Humacyte position peaked at $4K in Q2 2022.
70 funds tracked by Wall St. Rank held Humacyte as of Q3 2022.

Based on Point72 Hong Kong's 13F filing for Q3 2022, filed 14 Nov 2022.